Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03617328 · ClinicalTrials.gov registry record · Phase 1
Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma
A Phase 1 study, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT03617328 is a Phase 1 study that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 33 participants.
The verdict
NCT03617328, a Phase 1 study, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study evaluates whether it is safe to administer a peptide vaccine (6MHP) with adjuvants and the CDX-1127 monoclonal antibody, and whether the adjuvants and the CDX-1127 monoclonal antibody boost immune responses to the vaccine. In this study, the adjuvants are Montanide ISA-51 and polyICLC. The investigators will monitor these effects by performing tests in the laboratory on participants' blood and tissue from a vaccine site.
Interventions
- DRUG Montanide ISA-51
- BIOLOGICAL 6MHP
- DRUG polyICLC
- DRUG CDX-1127
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2018-11-13 |
| Est. Completion | 2024-01-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03617328
The ClinicalTrials.gov registry entry for NCT03617328 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Craig L Slingluff, Jr, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Montanide ISA-51 is the first listed.
NCT03617328 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03617328 about?
NCT03617328 is a clinical study titled "Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma". This study evaluates whether it is safe to administer a peptide vaccine (6MHP) with adjuvants and the CDX-1127 monoclonal antibody, and whether the adjuvants and the CDX-1127 monoclonal antibody boost immune responses to the vaccine. In this study, the adjuvants are Montanide ISA-51 and polyICLC. Th...
What is the current status of trial NCT03617328?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2018-11-13. Estimated completion is 2024-01-19.
What interventions are being tested in trial NCT03617328?
The interventions under investigation include: Montanide ISA-51 (DRUG), 6MHP (BIOLOGICAL), polyICLC (DRUG), CDX-1127 (DRUG).
Who is sponsoring clinical trial NCT03617328?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.